Post #5752
302
На конгрессах WMS 2026 в Хиросиме и AANEM 2026 в Орландо компания Dyne Therapeutics представила новые результаты I/II фазы исследования ACHIEVE препарата zeleciment basivarsen (z-basivarsen, DYNE-101) на основе антисмыслового олигонуклеотида для лечения миотонической дистрофии 1-го типа https://dynetx.gcs-web.com/news-releases/news-release-details/dyne-therapeutics-announces-additional-one-year-clinical-data-0
Dyne Therapeutics, Inc. Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic… - Data from a pooled dose group of participants initially enrolled in the multiple ascending dose (MAD) portion of ACHIEVE showed functional improvement versus baseline, versus placebo and versus a matched natural history cohort across multiple measures at… - ❤ 3
- 🔥 1